Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA

Tiffany M. Yu; Pravin U. Dugel; Julia A. Haller; Peter K. Kaiser; Renée J.G. Arnold

doi:10.2217/cer-2018-0057

Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA

Tiffany M. Yu
, Pravin U. Dugel
, Julia A. Haller
, Peter K. Kaiser
, Renée J.G. Arnold

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Background: Vitreomacular traction (VMT) treatment options include watchful waiting, vitrectomy and intravitreal ocriplasmin injection (Jetrea^®). This analysis used results from the recently completed OASIS randomized clinical trial to evaluate the 2-year budget impact of ocriplasmin injection availability for treatment of Stage I or II VMT without epiretinal membrane formation in a modeled US health plan. Materials & methods: VMT prevalence, treatment patterns and disease resolution rates were from literature, a US retinal-specialist survey and the OASIS trial. Medicare payment rates were applied and a national scenario analysis was conducted. Results: With ocriplasmin available, vitrectomy use and complications-related costs decreased. Budget impact of ocriplasmin to the health plan was US$143,599 over 2 years or US$0.0060 per-member per-month. Conclusion: Ocriplasmin was projected to be minimally cost-additive at US$0.0060 per-member per-month over 2 years.

Original language	English
Pages (from-to)	1195-1207
Number of pages	13
Journal	Journal of Comparative Effectiveness Research
Volume	7
Issue number	12
DOIs	https://doi.org/10.2217/cer-2018-0057
State	Published - 1 Dec 2018

Keywords

pharmacolysis
vitreoretinal adhesion
vitreoretinal traction

Access to Document

10.2217/cer-2018-0057

Cite this

@article{b5cb9be1d8bc4a329b08af023043f600,

title = "Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA",

abstract = "Background: Vitreomacular traction (VMT) treatment options include watchful waiting, vitrectomy and intravitreal ocriplasmin injection (Jetrea{\textregistered}). This analysis used results from the recently completed OASIS randomized clinical trial to evaluate the 2-year budget impact of ocriplasmin injection availability for treatment of Stage I or II VMT without epiretinal membrane formation in a modeled US health plan. Materials \& methods: VMT prevalence, treatment patterns and disease resolution rates were from literature, a US retinal-specialist survey and the OASIS trial. Medicare payment rates were applied and a national scenario analysis was conducted. Results: With ocriplasmin available, vitrectomy use and complications-related costs decreased. Budget impact of ocriplasmin to the health plan was US\$143,599 over 2 years or US\$0.0060 per-member per-month. Conclusion: Ocriplasmin was projected to be minimally cost-additive at US\$0.0060 per-member per-month over 2 years.",

keywords = "pharmacolysis, vitreoretinal adhesion, vitreoretinal traction",

author = "Yu, \{Tiffany M.\} and Dugel, \{Pravin U.\} and Haller, \{Julia A.\} and Kaiser, \{Peter K.\} and Arnold, \{Ren{\'e}e J.G.\}",

note = "Publisher Copyright: {\textcopyright} 2018 2018 Yu et al.",

year = "2018",

month = dec,

day = "1",

doi = "10.2217/cer-2018-0057",

language = "English",

volume = "7",

pages = "1195--1207",

journal = "Journal of Comparative Effectiveness Research",

issn = "2042-6305",

publisher = "Becaris Publishing Ltd",

number = "12",

}

TY - JOUR

T1 - Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA

AU - Yu, Tiffany M.

AU - Dugel, Pravin U.

AU - Haller, Julia A.

AU - Kaiser, Peter K.

AU - Arnold, Renée J.G.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background: Vitreomacular traction (VMT) treatment options include watchful waiting, vitrectomy and intravitreal ocriplasmin injection (Jetrea®). This analysis used results from the recently completed OASIS randomized clinical trial to evaluate the 2-year budget impact of ocriplasmin injection availability for treatment of Stage I or II VMT without epiretinal membrane formation in a modeled US health plan. Materials & methods: VMT prevalence, treatment patterns and disease resolution rates were from literature, a US retinal-specialist survey and the OASIS trial. Medicare payment rates were applied and a national scenario analysis was conducted. Results: With ocriplasmin available, vitrectomy use and complications-related costs decreased. Budget impact of ocriplasmin to the health plan was US$143,599 over 2 years or US$0.0060 per-member per-month. Conclusion: Ocriplasmin was projected to be minimally cost-additive at US$0.0060 per-member per-month over 2 years.

AB - Background: Vitreomacular traction (VMT) treatment options include watchful waiting, vitrectomy and intravitreal ocriplasmin injection (Jetrea®). This analysis used results from the recently completed OASIS randomized clinical trial to evaluate the 2-year budget impact of ocriplasmin injection availability for treatment of Stage I or II VMT without epiretinal membrane formation in a modeled US health plan. Materials & methods: VMT prevalence, treatment patterns and disease resolution rates were from literature, a US retinal-specialist survey and the OASIS trial. Medicare payment rates were applied and a national scenario analysis was conducted. Results: With ocriplasmin available, vitrectomy use and complications-related costs decreased. Budget impact of ocriplasmin to the health plan was US$143,599 over 2 years or US$0.0060 per-member per-month. Conclusion: Ocriplasmin was projected to be minimally cost-additive at US$0.0060 per-member per-month over 2 years.

KW - pharmacolysis

KW - vitreoretinal adhesion

KW - vitreoretinal traction

UR - https://www.scopus.com/pages/publications/85058065492

U2 - 10.2217/cer-2018-0057

DO - 10.2217/cer-2018-0057

M3 - Article

C2 - 30350717

AN - SCOPUS:85058065492

SN - 2042-6305

VL - 7

SP - 1195

EP - 1207

JO - Journal of Comparative Effectiveness Research

JF - Journal of Comparative Effectiveness Research

IS - 12

ER -

Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA

Abstract

Keywords

Access to Document

Fingerprint

Cite this